We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 27, 2022

Ramucirumab and Pembrolizumab vs Standard of Care in Advanced NSCLC Previously Treated With Immunotherapy

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A
J. Clin. Oncol 2022 Jun 03;[EPub Ahead of Print], KL Reckamp, MW Redman, KH Dragnev, K Minichiello, LC Villaruz, B Faller, T Al Baghdadi, S Hines, L Everhart, L Highleyman, V Papadimitrakopoulou, DR Gandara, K Kelly, RS Herbst

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading